Presentation to highlight clinical, regulatory and business opportunities in developing microbiome-directed therapeutics
Download this press release (289 KB).
ROSEVILLE, MN (March 12, 2018) — Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat debilitating diseases, today announced that Ken Blount, Ph.D., Chief Scientific Officer, will be a featured presenter during Microbiome Therapeutics Europe being held March 14-15, 2018 in Amsterdam.
Dr. Blount’s presentation, titled “Business, Regulatory, and Clinical Strategies to Develop New Microbiome-Directed Therapeutics,” will discuss the rapid growth of the microbiome therapeutics industry and the clinical and research discoveries that are being developed to create, manufacture and commercialize new and unique medicines to treat various diseases of the microbiome.
Dr. Blount remarked, “The microbiome therapeutics industry has witnessed exponential growth recently in terms of clinical progress and business opportunity. With companies like Rebiotix leading the way with late stage products and development of biostatistic tools like the MICROBIOME HEALTH INDEX™ (MHI™), we and other leaders in the microbiome space are in a unique position as scientists and business innovators to develop a foundation of understanding that can be applied across the industry. I look forward to presenting at Microbiome Therapeutics Europe to share and gain insight from the many esteemed attendees.”
Details of Dr. Blount’s presentation are as follows:
Microbiome Therapeutics Europe
Business, Regulatory, and Clinical Strategies to Develop New Microbiome-Directed Therapeutics
Tuesday, March 14, 2018
11:00 a.m. (Central European Time)
Novotel Amsterdam City
About Rebiotix Inc.
Rebiotix Inc. is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized, non-frozen, oral capsule formulation, which is currently the subject of an investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff. infection. In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
Rebiotix Media Contact:
Tiberend Strategic Advisors